Quest Diagnosticsvs.Natera
DGX vs NTRA · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Natera is about 1.7× larger than Quest Diagnostics by market cap.
Side by side
| DGX | NTRA | |
|---|---|---|
| Market cap | $26.1B | $44.6B |
| Price | $244.51 | $336.71 |
| Today | +0.3% | +2.7% |
| Return YTD | +40.5% | +43.1% |
| Return 1Y | +35.3% | +97.9% |
| P/E | 24.6 | — |
| P/S | 2.3 | 16.5 |
| P/B | 3.5 | 24.5 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Quest DiagnosticsDGX
A nationwide lab network that does routine testing at volume, with more advanced diagnostics and health data work on top.
Full DGX profile →NateraNTRA
Genetic testing put to three uses: Panorama screens pregnancies, Signatera works in oncology, and a third line covers transplant medicine.
Full NTRA profile →More DGX & NTRA comparisons
Other head-to-heads in the Diagnostics segment.
See where DGX and NTRA sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →